BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35154119)

  • 1. A Commercial Anti-TIF1γ ELISA Is Superior to Line and Dot Blot and Should Be Considered as Part of Routine Myositis-Specific Antibody Testing.
    Mulhearn B; Li D; McMorrow F; Lu H; McHugh NJ; Tansley SL
    Front Immunol; 2022; 13():804037. PubMed ID: 35154119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TIF1γ antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays.
    Labrador-Horrillo M; Martínez MA; Selva-O'Callaghan A; Trallero-Araguás E; Balada E; Vilardell-Tarrés M; Juarez C
    Ann Rheum Dis; 2012 Jun; 71(6):993-6. PubMed ID: 22294626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis.
    Fujimoto M; Murakami A; Kurei S; Okiyama N; Kawakami A; Mishima M; Sato S; Seishima M; Suda T; Mimori T; Takehara K; Kuwana M
    J Dermatol Sci; 2016 Dec; 84(3):272-281. PubMed ID: 27693019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
    Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
    Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients.
    Ogawa-Momohara M; Muro Y; Mitsuma T; Katayama M; Yanaba K; Nara M; Kakeda M; Kono M; Akiyama M
    Clin Exp Rheumatol; 2018; 36(6):990-995. PubMed ID: 29745874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity.
    Tansley SL; Li D; Betteridge ZE; McHugh NJ
    Rheumatology (Oxford); 2020 Aug; 59(8):2109-2114. PubMed ID: 32030410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort.
    Tarricone E; Ghirardello A; Rampudda M; Bassi N; Punzi L; Doria A
    J Immunol Methods; 2012 Oct; 384(1-2):128-34. PubMed ID: 22884621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
    Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
    Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1γ can result in experimental myositis.
    Okiyama N; Ichimura Y; Shobo M; Tanaka R; Kubota N; Saito A; Ishitsuka Y; Watanabe R; Fujisawa Y; Nakamura Y; Murakami A; Kayama H; Takeda K; Fujimoto M
    Ann Rheum Dis; 2021 Sep; 80(9):1201-1208. PubMed ID: 33811031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Anti-Transcription Intermediary Factor 1γ Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis.
    Venalis P; Selickaja S; Lundberg K; Rugiene R; Lundberg IE
    Arthritis Care Res (Hoboken); 2018 Apr; 70(4):648-651. PubMed ID: 28704599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort.
    Tansley SL; Simou S; Shaddick G; Betteridge ZE; Almeida B; Gunawardena H; Thomson W; Beresford MW; Midgley A; Muntoni F; Wedderburn LR; McHugh NJ
    J Autoimmun; 2017 Nov; 84():55-64. PubMed ID: 28663002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies.
    Hosono Y; Sie B; Pinal-Fernandez I; Pak K; Mecoli CA; Casal-Dominguez M; Warner BM; Kaplan MJ; Albayda J; Danoff S; Lloyd TE; Paik JJ; Tiniakou E; Aggarwal R; Oddis CV; Moghadam-Kia S; Carmona-Rivera C; Milisenda JC; Grau-Junyent JM; Selva-O'Callaghan A; Christopher-Stine L; Larman HB; Mammen AL
    Ann Rheum Dis; 2023 Feb; 82(2):246-252. PubMed ID: 36008132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera.
    Cavazzana I; Fredi M; Ceribelli A; Mordenti C; Ferrari F; Carabellese N; Tincani A; Satoh M; Franceschini F
    J Immunol Methods; 2016 Jun; 433():1-5. PubMed ID: 26906088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TIF1γ antibody and the expression of TIF1γ in idiopathic inflammatory myopathies.
    Kim Y; Song KS; Sohn EH; Kang SW; Yoo IS; Shim SC; Yoo SJ; Kim J
    Int J Rheum Dis; 2019 Feb; 22(2):314-320. PubMed ID: 30398003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis.
    Aussy A; Fréret M; Gallay L; Bessis D; Vincent T; Jullien D; Drouot L; Jouen F; Joly P; Marie I; Meyer A; Sibilia J; Bader-Meunier B; Hachulla E; Hamidou M; Huë S; Charuel JL; Fabien N; Viailly PJ; Allenbach Y; Benveniste O; Cordel N; Boyer O;
    Arthritis Rheumatol; 2019 Aug; 71(8):1360-1370. PubMed ID: 30896088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation.
    Aggarwal R; Oddis CV; Goudeau D; Fertig N; Metes I; Stephens C; Qi Z; Koontz D; Levesque MC
    Rheumatology (Oxford); 2014 Mar; 53(3):433-7. PubMed ID: 24255164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Case of Dermatomyositis Along with Esophageal Cancer and Screening of Serum Transcriptional Intermediary Factor 1 Gamma Antibodies in Various Cancer Patients.
    Sumazaki M; Kaneko K; Ito M; Oshima Y; Saito F; Ogata H; Shibuya K; Shimada H
    Am J Case Rep; 2020 Apr; 21():e922004. PubMed ID: 32312948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional intermediary factor 1 (TIF1) and anti-TIF1γ antibody-positive dermatomyositis.
    Kotobuki Y; Tonomura K; Fujimoto M
    Immunol Med; 2021 Mar; 44(1):23-29. PubMed ID: 32649853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Combination of IgA and IgG autoantibodies against Transcriptional Intermediary Factor-1γ contributes to the early diagnosis of Lung Cancer.
    Yu L; Lin X; Zhang L; Wu Q; Zhang S; Chen D; Pan X; Huang Y
    Int J Med Sci; 2020; 17(11):1561-1568. PubMed ID: 32669959
    [No Abstract]   [Full Text] [Related]  

  • 20. ELISA, protein immunoprecipitation and line blot assays for anti-TIF1-gamma autoantibody detection in cancer-associated dermatomyositis.
    Selickaja S; Galindo-Feria AS; Dani L; Mimori T; Rönnelid J; Holmqvist M; Lundberg IE; Venalis P
    Rheumatology (Oxford); 2022 Nov; 61(12):4991-4996. PubMed ID: 35579337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.